Radiation doses to the heart that occur during radiation therapy treatments for lung cancer, breast cancer and lymphoma can increase fatigue, cause difficulty breathing and lower capacity for physical activity in patients ...
Feb 14, 2020
0
4
In the United States, apart from some forms of skin cancer, breast cancer is the most common cancer in women. It is also the most common cause of death from cancer among Hispanic women and the second most common among all ...
Dec 5, 2019
0
1
(HealthDay)—Receiving treatment is associated with better survival for nonagenarians with non-small cell lung cancer (NSCLC), with the greatest survival benefit for stage I patients, according to a study published online ...
Nov 22, 2019
0
0
Adding precisely aimed, escalated doses of radiation after patients no longer respond to immunotherapy reinvigorates the immune system in some patients with metastatic non-small-cell lung cancer (NSCLC), increasing progression-free ...
Sep 26, 2019
0
1
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer. The ...
Sep 26, 2019
0
1
Mount Sinai researchers have developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation, an approach that also dramatically ...
Aug 2, 2019
0
1
A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the ...
Jul 25, 2019
2
1276
Despite the remarkable success of molecular targeted therapy in recent years, the rapid increase of drug resistance is a major obstacle to effective treatment of lung cancer.
Jul 9, 2019
0
0
When it comes to using radiation against lung cancer, preliminary clinical studies were pretty clear: More is better. So why did a large phase 3 clinical trial find exactly the opposite—that stage III non-small cell lung ...
Jun 26, 2019
0
0
For patients with operable non-small cell lung cancer (NSCLC), pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, ...
May 31, 2019
0
0
